Efficacy of Daratumumab-Based Regimens Compared to Standard of Care in Transplant-Eligible Multiple Myeloma: A Meta-Analysis

Daratumumab (dara) belongs to a class of monoclonal antibodies that target CD38 receptors expressed on multiple myeloma (MM) cells. It was first approved for MM treatment in 2015. The efficacy and safety of dara have been reported in many studies. In this analysis, we assessed the outcome of dara ad...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cureus
Main Authors: Menon, Trishala, Kataria, Saurabh, Adhikari, Ramesh, Khan, Hira, Khalid, Muhammad Zain, Saeeduddin, Mohammad Omar, Taj, Shafaq, Rehman, Usama, Tekin, Aysun, Singh, Romil
Formato: Artigo
Idioma:Inglês
Publicado em: Cureus 2021
Assuntos:
Internal Medicine
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8211300/
https://ncbi.nlm.nih.gov/pubmed/34155463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.15098
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados